Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.<strong>Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.</strong>
Product Specifications
Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
CAS Number
9007-83-4
Host
HEK 293
Origin Species
Human
Target
Spike RBD
Conjugation
Unconjugated
Tag
Human IgG1 | Human Kappa
Stability
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower._x000D_Please avoid repeated freeze-thaw cycles.
Purity
95%
Bioactivity
Immobilized SARS-CoV-2 S1 protein, His Tag at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).
Format
Powder
Buffer
PBS, pH7.4
Additives
Trehalose
Shipping Conditions
Room Temperature
Storage Conditions
-20°C
Documents
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog